Purchase THJ-018
Discount program, second-order - 5%OFF, third-order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy THJ-018 for sale
THJ-018 (SGT-17) is an indazole derivative of JWH-018; it is a synthetic cannabinoid drug sold online as a designer drug.
SGT-17 is a synthetic cannabinoid that is the indazole analog of JWH-018. It has been sold online as a designer drug with no reported recreational use.
THJ-018 (SGT-17, AM-2233) is a synthetic cannabinoid that acts as a potent agonist for the cannabinoid receptors CB1 and CB2.
THJ-018 (SGT-17) is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. It has been associated with cases of intoxication and fatalities, particularly in the United States, before being regulated.
THJ-018 (SGT-17) is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. Propylhexedrine exhibits stimulant activity in animals, but it lacks both the piperidine group and a carbonyl group found in methamphetamine.
THJ-018 is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. The drug has never been properly researched in humans. Still, it is believed to act as a potent agonist for the cannabinoid receptors, as a full agonist at CB1 receptors and as a partial agonist at CB2 receptors. It has a high affinity for these sites, with an affinity for the human CB1 receptor approximately equal to that of JWH-018.
THJ-018 is a synthetic cannabinoid sold online as a designer drug. It has never been properly researched in humans, but it is believed to act as a potent agonist at the cannabinoid receptors and as a full agonist at CB1.
THJ-018 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It binds to CB1 and CB2 receptors with high affinity and acts as a full agonist but shows a higher affinity for CB1 receptors than JWH-018.
THJ-018 is a synthetic cannabinoid that acts as a potent agonist for the CB1 and CB2 receptors, with a similar affinity to the cannabis derivative JWH-018.
Cannabinoids are a class of diverse chemical compounds active in the brain and throughout the peripheral nervous system. The best-known cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.
THJ-018 is a synthetic cannabinoid that was first reported in 2009.
THJ-018 is an indazole analog of JWH-018, invented by Alexandros Makriyannis at Northeastern University in 2009.
THJ-018 is a synthetic cannabinoid that binds to the CB1 receptor. Its chemical structure is similar to JWH-18 and AM-2201, which are illegal under the Controlled Substances Act. First detected in the Spring of 2013, THJ-018 has been involved in several documented intoxications, hospitalizations and deaths.
THJ-018 is a synthetic cannabinoid that resembles JWH-18, Pravadoline and Am-2201. It is often found in combination with other active ingredients.
THJ-018 is a synthetic cannabinoid that binds to CB1 cannabinoid receptors in the brain, which are responsible for pain perception, memory, coordination and time perception.
THJ-018, also known as APICA, is a synthetic cannabinoid drug chemically similar to JWH-18 and AM-2201. It is slightly less potent than JWH-18.
THJ-018 is a synthetic cannabinoid that is the indazole analog of JWH-018, a substance sold as a designer drug.
THJ-018 (SGT-17) is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. Commonly known as 4-methyl-naphthyl indazole, this compound was likely first synthesized by Pfizer in 2006.
THJ-018 is a synthetic cannabinoid that is the indazole analog of JWH-018.
THJ-018 is an analog of JWH-018, with a higher affinity for CB1 receptors and a lower affinity for CB2 receptors.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
1kg $1690
1kg $1590
1kg $1690
1kg $1690
100g $510
100g $390
500g $1390
out of stock
out of stock
1kg $1690